| Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors SC Meyer, RL Levine Clinical Cancer Research 20 (8), 2051-2059, 2014 | 181 | 2014 |
| CHZ868, a type II JAK2 inhibitor, reverses type I JAK inhibitor persistence and demonstrates efficacy in myeloproliferative neoplasms SC Meyer, MD Keller, S Chiu, P Koppikar, OA Guryanova, F Rapaport, ... Cancer cell 28 (1), 15-28, 2015 | 153 | 2015 |
| Translational implications of somatic genomics in acute myeloid leukaemia SC Meyer, RL Levine The Lancet Oncology 15 (9), e382-e394, 2014 | 153 | 2014 |
| Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors M Waibel, VS Solomon, DA Knight, RA Ralli, SK Kim, KM Banks, E Vidacs, ... Cell reports 5 (4), 1047-1059, 2013 | 148 | 2013 |
| Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis T Shimizu, L Kubovcakova, R Nienhold, J Zmajkovic, SC Meyer, ... Journal of Experimental Medicine 213 (8), 1479-1496, 2016 | 119 | 2016 |
| Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms S Stivala, T Codilupi, S Brkic, A Baerenwaldt, N Ghosh, H Hao-Shen, ... The Journal of clinical investigation 129 (4), 1596-1611, 2019 | 95 | 2019 |
| Cooperative epigenetic remodeling by TET2 loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity H Kunimoto, C Meydan, A Nazir, J Whitfield, K Shank, F Rapaport, ... Cancer cell 33 (1), 44-59. e8, 2018 | 90 | 2018 |
| Hyperbilirubinemia interferes with ADAMTS‐13 activity measurement by FRETS‐VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies SC Meyer, I Sulzer, B Lämmle, JAK Hovinga Journal of thrombosis and haemostasis 5 (4), 866-867, 2007 | 90 | 2007 |
| Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation SC Meyer, A O’Meara, AS Buser, A Tichelli, JR Passweg, M Stern Biology of Blood and Marrow Transplantation 19 (3), 440-444, 2013 | 69 | 2013 |
| A novel monoclonal antibody against the extracellular domain of GPIbβ modulates vWF mediated platelet adhesion C Perrault, S Moog, E Rubinstein, M Santer, MJ Baas, C de la Salle, ... Thrombosis and haemostasis 86 (11), 1238-1248, 2001 | 58 | 2001 |
| Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis SC Meyer, MD Keller, BA Woods, LM LaFave, L Bastian, M Kleppe, ... Blood, The Journal of the American Society of Hematology 124 (14), 2280-2284, 2014 | 54 | 2014 |
| Current management of thrombotic thrombocytopenic purpura JAK Hovinga, SC Meyer Current opinion in hematology 15 (5), 445-450, 2008 | 54 | 2008 |
| Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance S Stivala, S Gobbato, L Infanti, MF Reiner, N Bonetti, SC Meyer, ... Haematologica 102 (10), 1650, 2017 | 53 | 2017 |
| JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis J Grisouard, S Li, L Kubovcakova, TN Rao, SC Meyer, P Lundberg, ... Blood, The Journal of the American Society of Hematology 128 (6), 839-851, 2016 | 51 | 2016 |
| Mediator kinase phosphorylation of STAT1 S727 promotes growth of neoplasms with JAK-STAT activation II Nitulescu, SC Meyer, QJ Wen, JD Crispino, ME Lemieux, RL Levine, ... EBioMedicine 26, 112-125, 2017 | 47 | 2017 |
| Mechanisms of resistance to JAK2 inhibitors in myeloproliferative neoplasms SC Meyer Hematology/Oncology Clinics 31 (4), 627-642, 2017 | 42 | 2017 |
| Challenges and perspectives for therapeutic targeting of myeloproliferative neoplasms S Brkic, SC Meyer Hemasphere 5 (1), e516, 2021 | 32 | 2021 |
| A first case of congenital TTP on the African continent due to a new homozygous mutation in the catalytic domain of ADAMTS13 SC Meyer, R Jeddi, B Meddeb, E Gouider, B Lämmle, JA Kremer Hovinga Annals of hematology 87, 663-666, 2008 | 28 | 2008 |
| Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy S Brkic, S Stivala, A Santopolo, J Szybinski, S Jungius, JR Passweg, ... Leukemia 35 (10), 2875-2884, 2021 | 21 | 2021 |
| Genetics of myeloproliferative neoplasms J Szybinski, SC Meyer Hematology/oncology clinics of North America 35 (2), 217-236, 2021 | 20 | 2021 |
